heartburn

Summary

Summary: Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus.

Top Publications

  1. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study. Aliment Pharmacol Ther. 2009;29:1165-71 pubmed publisher
    Ability to predict freedom from heartburn relapse during maintenance therapy for healed reflux oesophagitis may facilitate optimal treatment choices for individual patients.
  2. Fass R, Chey W, Zakko S, Andhivarothai N, Palmer R, Perez M, et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29:1261-72 pubmed publisher
    ..The proportion of patients who respond to proton pump inhibitor (PPI) therapy is about 20% lower in those with non-erosive reflux disease (NERD) than in those with erosive oesophagitis...
  3. Galmiche J, Clouse R, Balint A, Cook I, Kahrilas P, Paterson W, et al. Functional esophageal disorders. Gastroenterology. 2006;130:1459-65 pubmed
    Functional esophageal disorders represent processes accompanied by typical esophageal symptoms (heartburn, chest pain, dysphagia, globus) that are not explained by structural disorders, histopathology-based motor disturbances, or ..
  4. Vakil N, Halling K, Ohlsson L, Wernersson B. Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol. 2013;108:767-74 pubmed publisher
    ..The aim of this exploratory analysis was to evaluate the Rome III criteria and the validity of the PDS/EPS subgrouping in primary care patients with upper gastrointestinal symptoms...
  5. Ribolsi M, Emerenziani S, Petitti T, Addarii M, Balestrieri P, Cicala M. Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. Dig Liver Dis. 2012;44:549-54 pubmed publisher
    ..Non-responder patients, evaluated under treatment, present symptoms which are related to non-acidic, mixed and proximal reflux episodes...
  6. Labenz J, Armstrong D, Zetterstrand S, Eklund S, Leodolter A. Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. Aliment Pharmacol Ther. 2009;29:959-66 pubmed publisher
    ..The ability to predict symptom response to reflux oesophagitis-healing therapy may optimize treatment decisions...
  7. El Serag H. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17-26 pubmed
    ..First, population-based studies that reported the prevalence of at least weekly heartburn and/or acid regurgitation were subjected to a time-trend analysis with a Poisson regression model...
  8. Kahrilas P, Howden C, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol. 2011;106:1419-25; quiz 1426 pubmed publisher
    The typical symptoms of gastroesophageal reflux disease (GERD) are heartburn and regurgitation...
  9. Fass R, Johnson D, Orr W, Han C, Mody R, Stern K, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011;106:421-31 pubmed publisher
    Nocturnal heartburn and related sleep disturbances are common among patients with gastroesophageal reflux disease (GERD)...

Scientific Experts

More Information

Publications62

  1. Kinoshita Y, Ashida K, Hongo M. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2011;33:213-24 pubmed publisher
    ..The efficacy of rabeprazole 5 mg/day for patients with non-erosive reflux disease (NERD) has not been reported in the literature...
  2. Jacobson B, Somers S, Fuchs C, Kelly C, Camargo C. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354:2340-8 pubmed
    ..An association between body-mass index (BMI)--the weight in kilograms divided by the square of the height in meters - and symptoms of gastroesophageal reflux disease in persons of normal weight has not been demonstrated...
  3. Howden C, Larsen L, Perez M, Palmer R, Atkinson S. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009;30:895-907 pubmed publisher
    ..Dexlansoprazole MR, a modified-release formulation of dexlansoprazole, an enantiomer of lansoprazole, effectively heals erosive oesophagitis...
  4. Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137:80-7, 87.e1 pubmed publisher
    ..Rebound acid hypersecretion (RAHS) has been demonstrated after 8 weeks of treatment with a proton-pump inhibitor (PPI). If RAHS induces acid-related symptoms, this might lead to PPI dependency and thus have important implications...
  5. Nocon M, Labenz J, Jaspersen D, Meyer Sabellek W, Stolte M, Lind T, et al. Association of body mass index with heartburn, regurgitation and esophagitis: results of the Progression of Gastroesophageal Reflux Disease study. J Gastroenterol Hepatol. 2007;22:1728-31 pubmed
    ..The aim of the present study was to analyze the impact of body mass index (BMI) on the severity and frequency of reflux symptoms and esophagitis in a large cohort of reflux patients...
  6. Dickman R, Parthasarathy S, Malagon I, Jones P, Han B, Powers J, et al. Comparisons of the distribution of oesophageal acid exposure throughout the sleep period among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther. 2007;26:41-8 pubmed
    ..Nocturnal gastro-oesophageal reflux diseases (GERD) can lead to oesophageal mucosal injury and extra-oesophageal complications...
  7. Metz D, Howden C, Perez M, Larsen L, O Neil J, Atkinson S. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009;29:742-54 pubmed publisher
    ..Dexlansoprazole MR heals all grades of erosive oesophagitis (EO)...
  8. Shapiro M, Green C, Faybush E, Esquivel R, Fass R. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups. Aliment Pharmacol Ther. 2006;23:321-9 pubmed
    ..Studies have demonstrated that patients with Barrett's oesophagus have the highest oesophageal acid exposure profile, followed by erosive oesophagitis and non-erosive reflux disease patients, but the exact extent of overlap remains unknown...
  9. McColl E, Junghard O, Wiklund I, Revicki D. Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients?. Am J Gastroenterol. 2005;100:11-8 pubmed
    ..This study aimed to determine the extent of agreement between clinicians and patients regarding assessments of reflux symptom severity in patients with gastroesophageal reflux disease...
  10. Frazzoni M, De Micheli E, Zentilin P, Savarino V. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther. 2004;20:81-8 pubmed
    Patients with endoscopy-negative heartburn can be subdivided into non-erosive reflux disease and functional heartburn on the basis of abnormal and normal, respectively, oesophageal acid exposure...
  11. Castell D, Kahrilas P, Richter J, Vakil N, Johnson D, Zuckerman S, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-83 pubmed
    ..This study compared esomeprazole with lansoprazole for the healing of erosive esophagitis and resolution of heartburn.
  12. Farup P, Juul Hansen P, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?. J Clin Gastroenterol. 2001;33:206-9 pubmed
    ..Rebound acid hypersecretion might occur after treatment with proton pump inhibitors. This study looks for a rebound aggravation of symptoms after short-term treatment with lansoprazole...
  13. Kahrilas P, Falk G, Johnson D, Schmitt C, Collins D, Whipple J, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther. 2000;14:1249-58 pubmed
    ..The pharmacologic profile of the new proton pump inhibitor esomeprazole has demonstrated advantages over omeprazole that suggest clinical benefits for patients with acid-related disease...
  14. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-31 pubmed
    ..The causes of adenocarcinomas of the esophagus and gastric cardia are poorly understood. We conducted an epidemiologic investigation of the possible association between gastroesophageal reflux and these tumors...
  15. Revicki D, Crawley J, Zodet M, Levine D, Joelsson B. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13:1621-30 pubmed
    Medical treatments for gastro-oesophageal reflux disease (GERD) vary in their ability to completely resolve heartburn and other symptoms...
  16. Talley N, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001;96:1998-2004 pubmed
    ..We aimed to evaluate the previously validated Gastrointestinal Symptoms Rating Scale (GSRS) and the Quality of Life in Reflux and Dyspepsia (QOLRAD) questionnaires for reliability and responsiveness to change over time...
  17. Tytgat G. Review article: management of mild and severe gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;17 Suppl 2:52-6 pubmed
    ..Also poorly understood is the lower yield of complete heartburn relief when the number of associated dyspeptic symptoms is high...
  18. Revicki D, Zodet M, Joshua Gotlib S, Levine D, Crawley J. Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health Qual Life Outcomes. 2003;1:73 pubmed
    ..This study evaluated the association between baseline heartburn severity and endpoint HRQL of patients treated for heartburn and the relationship between complete resolution of ..
  19. Rex D, Cummings O, Shaw M, Cumings M, Wong R, Vasudeva R, et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670-7 pubmed
    ..The population prevalence of Barrett's esophagus (BE) is uncertain. Our aim was to describe the prevalence of BE in a volunteer population...
  20. Puhan M, Guyatt G, Armstrong D, Wiklund I, Fallone C, Heels Ansdell D, et al. Validation of a symptom diary for patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2006;23:531-41 pubmed
    ..We assessed the validity and responsiveness of a symptom diary for patients with gastro-oesophageal reflux disease...
  21. Tack J, Caenepeel P, Arts J, Lee K, Sifrim D, Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut. 2005;54:1370-6 pubmed
    ..The aim of the present study was to study 24 hour pH monitoring in consecutive functional dyspepsia patients...
  22. Fass R, Quan S, O Connor G, Ervin A, Iber C. Predictors of heartburn during sleep in a large prospective cohort study. Chest. 2005;127:1658-66 pubmed
    Nocturnal gastroesophageal reflux, which may result in nocturnal heartburn, has been demonstrated to be associated with a more severe form of gastroesophageal reflux disease (GERD)...
  23. Fass R, Fennerty M, Vakil N. Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-14 pubmed
    ..Treatment with acid inhibitory agents is effective, and proton pump inhibitors are the most effective form of therapy...
  24. Gold B, Gunasekaran T, Tolia V, Wetzler G, Conter H, Traxler B, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr. 2007;45:520-9 pubmed
    ..A secondary aim was to assess changes in GERD symptoms after esomeprazole therapy...
  25. Pacheco Galván A, Hart S, Morice A. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm. Arch Bronconeumol. 2011;47:195-203 pubmed publisher
    ..paradigm of airway reflux as synonymous with the classic gastro-oesophageal reflux disease (GORD) causing heartburn has been overturned...
  26. Dutta S, Agrawal K, Mahmoud M. Modulation of salivation and heartburn in response to the site of acid infusion in the human oesophagus. Aliment Pharmacol Ther. 2010;32:795-800 pubmed publisher
    ..This may depend upon the height of acid wave and magnitude of oesophageal mucosal exposure. Interestingly, the effect of site of acid infusion upon salivary secretion and heartburn has not been examined in any detail.
  27. Chen C, Yi C, Liu T, Orr W. Altered sensorimotor responses to esophageal acidification in older adults with GERD. Scand J Gastroenterol. 2010;45:1150-5 pubmed publisher
    ..This study aimed to compare the effect of intraluminal acidification on esophageal sensory perception and motor activity between older and younger patients with gastroesophageal reflux disease (GERD)...
  28. Reimer C, Bytzer P. [Adverse events associated with long-term use of proton pump inhibitors]. Ugeskr Laeger. 2012;174:2289-93 pubmed
    ..Prolonged PPI use may be a weak risk factor for certain fractures and results in hypergastrinaemia and parietal cell hyperplasia leading to rebound acid hypersecretion, which may induce symptoms on withdrawal of therapy...
  29. Bulsiewicz W, Shaheen N, Hansen M, Pruitt A, Orlando R. Effect of amiloride on experimental acid-induced heartburn in non-erosive reflux disease. Dig Dis Sci. 2013;58:1955-9 pubmed publisher
    Acid-sensing ion channels (ASICs) are esophageal nociceptors that are candidates to mediate heartburn in non-erosive reflux disease (NERD). Amiloride, a diuretic, is known to inhibit ASICs...
  30. Sigterman K, van Pinxteren B, Bonis P, Lau J, Numans M. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;:CD002095 pubmed publisher
    Approximately 25% of adults regularly experience heartburn, a symptom of gastro-oesophageal reflux disease (GORD). Most patients are treated empirically (without specific diagnostic evaluation e.g. endoscopy...
  31. Viazis N, Karamanolis G, Anastasiou J, Keyoglou A, Vlachogiannakos J, Ladas S, et al. Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn. Eur J Gastroenterol Hepatol. 2013;25:1450-5 pubmed publisher
    To compare the incidence of persistent abnormal acid exposure, hypersensitive esophagus (HE), and functional heartburn (FH) in obese/overweight and normal-weight patients referred for impedance-pH monitoring, because of persisting ..
  32. Stiefelhagen P. [Gastroenterology in family practice. Updates for your "stomach patient"]. MMW Fortschr Med. 2006;148:4-6 pubmed
  33. Lamb P, Myers J, Jamieson G, Thompson S, Devitt P, Watson D. Long-term outcomes of revisional surgery following laparoscopic fundoplication. Br J Surg. 2009;96:391-7 pubmed publisher
    ..A small proportion of patients who have laparoscopic antireflux procedures require revisional surgery. This study investigated long-term clinical outcomes...
  34. Roila F, Ruggeri B, Ballatori E, Del Favero A, Tonato M. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol. 2014;32:101-6 pubmed publisher
    ..The aim of this study was to verify whether dexamethasone is superior to aprepitant in preventing delayed emesis in patients receiving the same prophylaxis for acute emesis...
  35. Liu T, Yi C, Lei W, Hung J, Chen C, Orr W. Effects of esophageal capsaicin instillation on acid induced excitation of secondary peristalsis in humans. J Gastroenterol Hepatol. 2016;31:364-9 pubmed publisher
    ..Our aim was to investigate whether intra-esophageal capsaicin infusion can influence symptom perception and physiological alteration of secondary peristalsis subsequent to acid infusion...
  36. Altun R, Akbas E, Yildirim A, Ocal S, Korkmaz M, Selcuk H. Frequency of eosinophilic esophagitis in patients with esophageal symptoms: a single-center Turkish experience. Dis Esophagus. 2013;26:776-81 pubmed publisher
    ..6% (n = 8; four men and four women). Mean age at diagnosis was 40.2 ± 8 years. Heartburn was the predominant symptom in patients (75% of the patients), and 87...
  37. Lampen Smith A, Young J, O Rourke M, Balram A, Inns S. Blinded randomised controlled study of the effect of a discharge communication template on proton pump inhibitor prescribing. N Z Med J. 2012;125:30-6 pubmed
  38. Furuta K, Adachi K, Arima N, Tanaka S, Miki M, Azumi T, et al. [Study on the recognition of upper abdominal symptoms by Japanese adults ]. Nihon Shokakibyo Gakkai Zasshi. 2008;105:817-24 pubmed
    ..symptoms, which might cause hospital visit and only a few subjects thought that they make a hospital visit by heartburn, acid regurgitation and early satiety...
  39. Khan B, Sodhi J, Zargar S, Javid G, Yattoo G, Shah A, et al. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J Gastroenterol Hepatol. 2012;27:1078-82 pubmed publisher
    Nocturnal gastro-esophageal reflux causes heartburn and sleep disturbances impairing quality of life. Lifestyle modifications, like bed head elevation during sleep, are thought to alleviate the symptoms of gastroesophageal reflux...
  40. Navarro Rodríguez F, Chaves R, Dib R, Navarro Rodriguez T. The importance of socioeconomic factors in symptoms of heartburn. Rev Gastroenterol Mex. 2011;76:209-16 pubmed
    ..Patients' socioeconomic status is rarely assessed during medical consultations...
  41. Sawaya R, MacGill A, Parkman H, Friedenberg F. Use of the Montreal global definition as an assessment of quality of life in reflux disease. Dis Esophagus. 2012;25:477-83 pubmed publisher
    ..Whether heartburn and regurgitation symptoms would be characterized as more troublesome in those with confirmed pathologic acid ..
  42. Furuta T, Shimatani T, Sugimoto M, Ishihara S, Fujiwara Y, Kusano M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Resea. J Gastroenterol. 2011;46:1273-83 pubmed publisher
    ..We investigated the predictive marker of the efficacy of PPI for GERD patients including NERD and RE treated with standard and increased doses of a PPI...
  43. Patti M, Waxman I. Gastroesophageal reflux disease: From heartburn to cancer. World J Gastroenterol. 2010;16:3743-4 pubmed
    ..Recently, major advances have been made in the endoscopic treatment of Barrett's esophagus, therefore limiting the role of surgery in the treatment of this disease...
  44. Poh C, Gasiorowska A, Navarro Rodriguez T, Willis M, Hargadon D, Noelck N, et al. Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. Gastrointest Endosc. 2010;71:28-34 pubmed publisher
    Failure of proton pump inhibitor (PPI) treatment in patients with heartburn is very common. Because endoscopy is easily accessible, it is commonly used as the first evaluative tool in these patients.
  45. Ozawa S, Kumai K, Higuchi K, Arakawa T, Kato M, Asaka M, et al. Short-term and long-term outcome of endoluminal gastroplication for the treatment of GERD: the first multicenter trial in Japan. J Gastroenterol. 2009;44:675-84 pubmed publisher
    ..The aim of this study was to evaluate the short-term and long-term effectiveness and safety of ELGP for GERD in the Japanese population...
  46. Sveen S. Symptom check: is it GERD?. J Contin Educ Nurs. 2009;40:103-4 pubmed
    ..In addition to the classic symptoms of GERD-acid reflux and heartburn-several atypical conditions may also be present...
  47. Zeng J, Zuo X, Li Y, Wei W, Lv G. Tegaserod for dyspepsia and reflux symptoms in patients with chronic constipation: an exploratory open-label study. Eur J Clin Pharmacol. 2007;63:529-36 pubmed
  48. Kouzu T, Hishikawa E, Watanabe Y, Inoue M, Satou T. [Epidemiology of GERD in Japan]. Nihon Rinsho. 2007;65:791-4 pubmed
    ..of Japanese patients with gastroesophageal reflux disease(GERD), we investigated the prevalences of heartburn, reflux esophagitis(RE), hiatus hernia and Barrett's mucosa, and assessed the correlations among them...
  49. Savarino E, De Bortoli N, Zentilin P, Martinucci I, Bruzzone L, Furnari M, et al. Alginate controls heartburn in patients with erosive and nonerosive reflux disease. World J Gastroenterol. 2012;18:4371-8 pubmed publisher
    ..To evaluate the effect of a novel alginate-based compound, Faringel, in modifying reflux characteristics and controlling symptoms...
  50. Kroupa R, Hep A, Dolina J, Valek V, Matyasova Z, Prokesova J, et al. Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results. Dis Esophagus. 2010;23:100-5 pubmed publisher
    ..The main adverse effect was heartburn that appeared in 17 patients (36%)...
  51. Dean B, Aguilar D, Johnson L, Fass R, Orr W, McGuigan J, et al. The relationship between the prevalence of nighttime gastroesophageal reflux disease and disease severity. Dig Dis Sci. 2010;55:952-9 pubmed publisher
    ..Nighttime gastrointestinal reflux disease (GERD) prevalence and severity estimates vary substantially across studies...
  52. Vakil N, Huff F, Cundy K. Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease--insights into study design for transient lower sphincter relaxation inhibitors. Aliment Pharmacol Ther. 2013;38:107-17 pubmed publisher
    ..Arbaclofen placarbil is a pro-drug of the gamma-aminobutyric acid-B agonist R-baclofen that has been shown to reduce reflux episodes in patients with gastro-oesophageal reflux disease (GERD)...
  53. Frazzoni M, De Bortoli N, Frazzoni L, Tolone S, Savarino V, Savarino E. Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. Dig Dis Sci. 2017;62:1881-1889 pubmed publisher
    b>Heartburn is the most specific symptom of gastroesophageal reflux disease (GERD). In clinical practice, heartburn relief by a proton pump inhibitor (PPI) trial does suffice to confirm GERD...